Lisa Chen

发表

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.

I. Puzanov, M. Milhem, H. Kaufman, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.

J. Malvehy, R. Dummer, J. Kirkwood, 2016 .

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

M. Ross, K. Delman, I. Puzanov, 2016, Annals of Surgical Oncology.

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)

J. Malvehy, R. Dummer, J. Kirkwood, 2015, Journal of Immunotherapy for Cancer.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Michael E. Lassman, J. Malvehy, R. Dummer, 2017, Cell.

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

A. Hauschild, M. Ross, I. Puzanov, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

E. Van Cutsem, J. Tabernero, N. Tebbutt, 2014, Clinical Cancer Research.

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma

A. Hauschild, I. Puzanov, C. Garbe, 2019, British Journal of Cancer.

Oncotargets and Therapy Dovepress

K. Harrington, Z. Szabo, H. Kaufman, 2022 .

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma

M. Ross, K. Harrington, J. Nemunaitis, 2016, Head & neck.

A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265).

J. Malvehy, R. Dummer, J. Kirkwood, 2016 .

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Michael E. Lassman, J. Malvehy, R. Dummer, 2017, Cell.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, David C. Smith, A. Hauschild, 2016, Journal of Translational Medicine.

Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma

M. Ross, I. Puzanov, M. Milhem, 2016 .

Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer

H. Hurwitz, D. Goldstein, H. Burris, 2015, Cancer Chemotherapy and Pharmacology.

Erratum: Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (Cell (2017) 170(6) (1109–1119.e10) (S0092867417309522) (10.1016/j.cell.2017.08.027))

Michael E. Lassman, J. Malvehy, R. Dummer, 2018 .

24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma

J. Malvehy, R. Dummer, J. Kirkwood, 2015 .

Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors.

V. Ganju, J. Coward, G. Richardson, 2019, Journal of Clinical Oncology.

A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma.

R. Dummer, J. Kirkwood, A. Ribas, 2015 .

Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma.

A. Hauschild, M. Ross, I. Puzanov, 2017 .

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage iiiB / c and iVM 1 a melanoma : subanalysis of the Phase iii OPTiM trial

Z. Szabo, H. Kaufman, F. Collichio, 2016 .

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

E. Van Cutsem, J. Tabernero, N. Tebbutt, 2014, Clinical Cancer Research.

A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors.

L. C. Chen, J. Baselga, J. Tabernero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.